Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Respiratory Infections
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Respiratory Infections
    Inhaled Corticosteroids in Patients With Stable Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis - (JAMA)
    Use of Inhaled Corticosteroids for COPD Does Not Appear to Improve Survival, May Increase Risk for Pneumonia - (DGNews)
    TopAbstracts in Respiratory Infections 11/24/2008 - (DGNews)
    TopAbstracts in Respiratory Infections 11/10/2008 - (DGNews)
    Genetic Markers Point to Increased Risk of Infection in Patients With Rheumatoid Arthritis: Presented at ACR-ARHP - (DGDispatch)

    News archive

     Recent webcasts/CME - Respiratory Infections
      Emergence of Methicillin-Resistant Staphylococcus aureus
      Pulmonary Complications of Anti-Tumor Necrosis Factor-a Therapy
      Current Issues in the Management of Respiratory Tract Congestion
      Evaluation and Management of Pneumonia in Older Adults
      The Latest on Community-Acquired Pneumonia

      Webcasts/CME archive

       Recent cases - Respiratory Infections
        Acute Myocardial Infarction and Pulmonary Tuberculosis in a Young Female Patient: A Case Report
        Massive Retroperitoneal Tubercular Abscess Mimicking a Leaking Abdominal Aortic Aneurysm: A Case Report
        Hypertrophic Pulmonary Osteoarthropathy Secondary to Bronchial Adenocarcinoma and Coexisting Pulmonary Tuberculosis: A Case Report
        Nocardia - Opportunistic Chest Infection in Elderly: A Case Report
        Thalidomide-Related Eosinophilic Pneumonia: A Case Report and Brief Literature Review

        Cases archive
          




        my personal edition > respiratory infections > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Once-Daily Telithromycin Proves Safe, Effective for Community-Acquired Respiratory Infections: Presented at ICAAC

        By Michael Smith

        SAN DIEGO, CA -- October 3, 2002 -- A head-to-head study involving 24,000 patients has shown that once-daily telithromycin is as safe and effective as twice-daily amoxicillin-clavulanate (AMC) in the treatment of community-acquired upper respiratory tract infections.

        Such infections are among the most frequently seen in outpatients, said Dr. Paul Iannini, MD, of Danbury Hospital, Danbury, Connecticut, in a presentation here at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). If left untreated, he said, they can cause significant mortality.

        Telithromycin, a ketolide, is the first member of a new class of antibacterial agents developed to treat such infections; it has a broad spectrum, is active against bacteria resistant to other agents, and can be given once-daily, thus potentially improving compliance.

        The goal of the study was to assess the safety and efficacy of telithromycin in a range of upper respiratory infections, including pneumonia, acute sinusitis, and acute exacerbation of chronic bronchitis, in a usual-care setting. Amoxicillin-clavulanate was chosen as the comparator because its safety and efficacy profiles are well known, Dr. Iannini said.

        Patients were randomised on their first visit and evaluated on their second visit (day 17 to 22) and on their third (day 30 to 35). In both arms, 8.9 percent of patients presented with pneumonia, 31 percent with acute exacerbation of bronchitis, and 60 percent with acute sinusitis.

        The safety profile for the two arms was similar. Most treatment-emergent adverse effects were mild and transient; the most common were gastrointestinal disorders. The incidence of serious adverse events was 1.3 percent in the telithromycin group and 1.1 percent for AMC.

        The efficacy profiles were also similar. The hospitalisation rate at the second visit for telithromycin was 1.1 percent, compared to 0.97 percent for AMC; on the third visit, the rates were 0.75 and 0.66, respectively.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send